Evidence map›Paper›PMID 42621997›Full record

ArticleThe World Allergy Organization journal2026

A short-course and season-oriented Stapokibart strategy for moderate-to-severe seasonal allergic rhinitis: Real-world evidence from Northern China.

Xu Li, Peize Liu, Mengwei Wu, He Geng, Chao Wang, Ling Zhou, Guangmei Yuan, Haoyuan Li, Yan Sun, Na Liu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xu LiDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Peize LiuDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Mengwei WuDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
He GengDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Chao WangDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Ling ZhouDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Guangmei YuanDepartment of Otolaryngology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China.
Haoyuan LiDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Yan SunDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Na LiuDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Yunqing ZhangDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Na ZhangDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Tingting GaoDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Jingjing WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.
Peng JinDepartment of Otolaryngology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China.
Lili ZhiDepartment of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Seasonal allergic rhinitis (SAR) imposes a substantial disease burden worldwide. In Northern China, Methods: This multicenter observational case series included 37 adults with Results: Stapokibart produced rapid and sustained symptom improvement. TNSS decreased from 9.22 ± 1.11 at baseline to 2.87 ± 1.32 at week 1 and 0.97 ± 0.83 at week 4, remaining low through week 16 (0.19 ± 0.40). Similar improvements were observed in VAS and RQLQ scores, accompanied by a marked reduction in medication use. FnNO10 decreased significantly by week 4 and remained suppressed at week 16, whereas total IgE showed no significant change. No serious adverse events occurred. Conclusions: A two-dose, season-oriented Stapokibart regimen achieved rapid and durable symptom control with favorable safety in real-world SAR. This pragmatic strategy may represent a practical biologic approach aligned with seasonal disease dynamics.

Indexed as

AllergicAntibodiesArtemisiaBiological therapyHumanizedInterleukin-4 receptor alpha subunitMonoclonalRhinitisSeasonal

Identifiers

PMID42621997
PMCPMC13488042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.